摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

氢化可的松21-戊酸酯 | 6678-00-8

中文名称
氢化可的松21-戊酸酯
中文别名
——
英文名称
hydrocortisone 17-valerate
英文别名
hydrocortisone 21-valerate;hydrocortisone-21-valerate;cortisol 21-valerate;hydrocortisone valerate;11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 21-valerate;[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] pentanoate
氢化可的松21-戊酸酯化学式
CAS
6678-00-8
化学式
C26H38O6
mdl
——
分子量
446.584
InChiKey
XHDMDWMKAYYIRK-FZNHGJLXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    182-186°C
  • 沸点:
    515.91°C (rough estimate)
  • 密度:
    1.0663 (rough estimate)
  • 溶解度:
    氯仿(微溶)、DMSO(微溶)、乙醇(微溶)、甲醇(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.81
  • 拓扑面积:
    101
  • 氢给体数:
    2
  • 氢受体数:
    6

SDS

SDS:d6553240694eca6705f50b306b320a1f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    Relative affinity of 17α- and/or 21-esters and 17α,21-diesters of cortisol for a glucocorticoid receptor from rat thymocytes
    摘要:
    The affinity, relative to cortisol (1), of 17 alpha- and 21-esters and 17 alpha,21-diesters of cortisol for the glucocorticoid receptor of rat thymus cytosol was determined by a competitive binding assay which used [3H]dexamethasone. Esterification of the 21-hydroxy group of cortisol caused a loss of relative affinity to 0.046 for acetate and 0.32 for valerate. Esterification of the 17 alpha-hydroxy group resulted in an increase in relative affinity to 1.14 for acetate, 12.4 for butyrate, and 11.5 for valerate. Diesters had relative affinities which reflected both trends. Thus, the 21-acetate, 21-propionate, 21-butyrate, and 21-valerate of cortisol 17-acetate had relative affinities of 0.036, 0.093, 0.152, and 0.272. The 21-acetate, 21-propionate, and 21-butyrate of cortisol 17-valerate had relative affinities of 0.76, 1.17, and 1.33.
    DOI:
    10.1021/jm00348a027
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
    申请人:REDX PHARMA PLC
    公开号:WO2016051193A1
    公开(公告)日:2016-04-07
    This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.
    这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地,该发明涉及用作集落刺激因子1受体(cFMS)调节剂(例如cFMS抑制剂)的化合物。这项发明还涉及制备这些化合物的方法,这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言,该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
  • [EN] CHEMOKING RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINES
    申请人:ABBOTT LAB
    公开号:WO2013010453A1
    公开(公告)日:2013-01-24
    Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    本文揭示了化学受体拮抗剂的化学式(I),其中G1、X1、X2和X3如规范中所定义。还描述了包含这种化合物的组合物;以及使用这种化合物和组合物治疗疾病和疾病的方法。
  • [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
    申请人:ABBVIE INC
    公开号:WO2016168641A1
    公开(公告)日:2016-10-20
    The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    这项发明提供了三环杂环化合物,其药用盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
  • Novel Tricyclic Compounds
    申请人:Wishart Neil
    公开号:US20090312338A1
    公开(公告)日:2009-12-17
    The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    这项发明提供了一个符合Formula (I)的化合物,其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
  • [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
    申请人:GENENTECH INC
    公开号:WO2017205538A1
    公开(公告)日:2017-11-30
    The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.
    本发明涉及一种化合物公式(I)及其盐,其中R1、R2X和Y具有本文中定义的任何值,以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式(I)化合物或其药学上可接受的盐的药物组合物,以及在治疗各种CBP和/或EP300介导的疾病,如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B